1. Home
  2. RLMD
  3. RLMD News

Latest Relmada Therapeutics Inc. (RLMD) News on June 27, 2025

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
RLMD

GlobeNewswire

10 days ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

RLMD

Argus Research

16 days ago

Daily – Vickers Top Insider Picks for 06/11/2025

RLMD

Argus Research

17 days ago

Daily – Vickers Top Insider Picks for 06/10/2025

RLMD

Argus Research

18 days ago

Daily – Vickers Top Insider Picks for 06/09/2025

RLMD

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 05/30/2025

RLMD

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 05/29/2025

RLMD

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 05/28/2025

RLMD

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 05/27/2025

RLMD

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 05/23/2025

RLMD

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 05/22/2025

RLMD

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 05/21/2025

RLMD

Thomson Reuters StreetEvents

a month ago

Q1 2025 Relmada Therapeutics Inc Earnings Call

Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ...
RLMD

GuruFocus.com

a month ago

Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ...

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
RLMD

GlobeNewswire

a month ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
RLMD

GlobeNewswire

2 months ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

RLMD

MT Newswires

2 months ago

Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
RLMD

GlobeNewswire

2 months ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
RLMD

GlobeNewswire

2 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
RLMD

GlobeNewswire

2 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
RLMD

GlobeNewswire

2 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Relmada Therapeutics To Present NDV-01 Data at AUA2025
RLMD

GlobeNewswire

2 months ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

RLMD

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Relmada Therapeutics Inc Earnings Call

Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ...
RLMD

GuruFocus.com

3 months ago

Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ...

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
RLMD

GlobeNewswire

3 months ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
RLMD

GlobeNewswire

3 months ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
RLMD

GlobeNewswire

3 months ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Relmada acquires Tourette’s therapy rights from Asarina
RLMD

Pharmaceutical Technology

5 months ago

Relmada acquires Tourette’s therapy rights from Asarina

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
RLMD

GlobeNewswire

5 months ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

US Penny Stocks To Watch In January 2025
RLMD

Simply Wall St.

6 months ago

US Penny Stocks To Watch In January 2025

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 12/09/2024

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
RLMD

GlobeNewswire

7 months ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 12/06/2024

RLMD

MT Newswires

7 months ago

Relmada Shares Continue Downward Spiral After Downgrades

Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile
RLMD

TipRanks

7 months ago

Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 12/05/2024

RLMD

MT Newswires

7 months ago

Sector Update: Health Care Stocks Edge Lower Late Afternoon

RLMD

MT Newswires

7 months ago

Top Midday Decliners

RLMD

MT Newswires

7 months ago

Relmada Therapeutics' Late-Stage Trial of REL-1017 Deemed 'Futile' -- Shares Decline Pre-Bell

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance
RLMD

GlobeNewswire

7 months ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 12/04/2024

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 12/03/2024

US Penny Stocks Spotlight: LiveOne And 2 Other Promising Picks
RLMD

Simply Wall St.

7 months ago

US Penny Stocks Spotlight: LiveOne And 2 Other Promising Picks

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 12/02/2024

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 11/29/2024

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 11/27/2024

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 11/26/2024

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 11/25/2024

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 11/22/2024

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 11/21/2024

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 11/20/2024

Relmada Therapeutics to Present at Jefferies London Healthcare Conference
RLMD

GlobeNewswire

7 months ago

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 11/19/2024

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 11/18/2024

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 11/15/2024

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
RLMD

GlobeNewswire

7 months ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 11/14/2024

RLMD

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 11/13/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 11/11/2024

RLMD

Market Exclusive

8 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector 11-11-2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 11/08/2024

Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ...
RLMD

GuruFocus.com

8 months ago

Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ...

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
RLMD

PR Newswire

8 months ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 11/07/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 11/06/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 11/05/2024

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
RLMD

GlobeNewswire

8 months ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 11/04/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 11/01/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 10/31/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 10/30/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 10/29/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 10/28/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 10/25/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 10/24/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 10/23/2024

3 US Penny Stocks To Monitor In October 2024
RLMD

Simply Wall St.

8 months ago

3 US Penny Stocks To Monitor In October 2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 10/22/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 10/21/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 10/18/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 10/17/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 10/16/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 10/15/2024

RLMD

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 10/14/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 10/11/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 10/10/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 10/09/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 10/08/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 10/07/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 10/04/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 10/03/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 10/02/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 10/01/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 09/30/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 09/27/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 09/26/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 09/25/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 09/24/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 09/23/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 09/20/2024

RLMD

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 09/19/2024

Share on Social Networks: